Osteomyelitis — infection of bone — is one of the most serious and challenging complications of diabetic foot disease. It develops in an estimated 10–15% of diabetic foot ulcers and in up to 20% of moderate infections and more than 50–60% of severe infections. When left undiagnosed or inadequately treated, diabetic foot osteomyelitis (DFO) carries a high risk of prolonged antibiotic therapy, repeated surgery, and major limb amputation. A growing body of peer-reviewed research has refined how clinicians identify and manage this condition, offering more targeted diagnostic pathways and increasingly conservative treatment strategies.
Recognizing Diabetic Foot Osteomyelitis: Clinical Clues
DFO most often arises as a complication of a pre-existing foot ulcer, particularly one that is deep, longstanding, or slow to heal. The classic clinical marker is a “sausage toe” — a swollen, erythematous digit — but this finding is not always present. A more reliable bedside test is the probe-to-bone (PTB) test, in which a sterile metal probe is passed through the ulcer. Contact with a hard, gritty surface strongly suggests cortical bone involvement. According to the 2023 IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-Related Foot Infections, a positive PTB result in a high-risk wound substantially raises the likelihood of osteomyelitis and should guide further workup.
Laboratory markers such as elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell count support the clinical suspicion for infection, though none are specific for bone involvement. A 2024 meta-analysis and systematic review published in Wound Repair and Regeneration (Ansert et al., 2024) found that while no single biomarker is sufficient to confirm or exclude DFO, the combination of elevated ESR and CRP with clinical findings substantially improves diagnostic accuracy.
Imaging and Bone Biopsy: The Diagnostic Workup
Plain radiographs are the appropriate first imaging step when osteomyelitis is suspected. Bony erosion, cortical destruction, or periosteal reaction on plain X-ray, combined with a compatible clinical picture, may be sufficient to confirm the diagnosis. However, radiographic changes often lag several weeks behind actual bone infection, limiting sensitivity in early disease.
When plain films are inconclusive, magnetic resonance imaging (MRI) is the preferred advanced modality. It provides high sensitivity and specificity for bone marrow involvement and allows assessment of adjacent soft tissue extension, joint involvement, and abscess formation. A study published in the Journal of the American Podiatric Medical Association (Teh et al., 2020) confirmed MRI as highly accurate in biopsy-proven DFO, though it noted that variation in imaging interpretation and clinical context can affect reliability — underscoring the need for integrated clinical and radiological assessment.
The gold standard for definitive diagnosis remains bone biopsy with culture and histopathology. A systematic review and meta-analysis published in Clinical Infectious Diseases (Senneville et al., 2020) found that percutaneous bone biopsy yielded positive cultures in approximately 84% of cases with suspected DFO. Importantly, bone-derived cultures are more likely than superficial swabs to identify the true causative organism, directly informing targeted antibiotic therapy. Twelve-month amputation-free survival was significantly higher among patients with culture-positive bone biopsy results, reinforcing the diagnostic and prognostic value of this procedure.
Medical Versus Surgical Management
Management of DFO requires an individualized approach balancing infection control, wound healing, and limb preservation. Two broad strategies exist: conservative (antibiotic-based) management and surgical intervention with or without adjunctive antibiotics.
The 2023 IWGDF/IDSA guidelines recommend that patients with uncomplicated forefoot osteomyelitis — particularly those without peripheral artery disease, without exposed bone requiring resection, and without systemic sepsis — may be treated successfully with antibiotic therapy alone, avoiding surgery. A narrative review published in Medicina (Lázaro-Martínez et al., 2021) supports this approach, noting remission rates comparable to surgical cohorts in appropriately selected patients.
For patients requiring surgery, the current emphasis is on conservative resection: removing infected and necrotic bone while preserving as much functional tissue as possible. Ray amputations, sesamoidectomies, and partial calcanectomies are preferred over major limb amputation whenever vascular supply is adequate. Multidisciplinary limb salvage teams — integrating podiatry, vascular surgery, infectious disease, orthopaedics, and endocrinology — have been shown to significantly improve outcomes, reduce amputation rates, and shorten hospital stays.
Antibiotic Therapy: Evolving Evidence on Duration
Antibiotic therapy in DFO has traditionally ranged from 6 to 12 weeks, but recent evidence challenges the necessity of prolonged courses. A prospective randomized noninferiority trial published in Clinical Infectious Diseases (Tone et al., 2015) compared 6 weeks versus 12 weeks of antibiotic therapy for nonsurgically treated DFO and found no statistically significant difference in remission rates — suggesting that extended courses beyond 6 weeks may not offer added benefit.
More recent trials have further compressed treatment timelines. A study in Clinical Infectious Diseases (Lazaro-Martinez et al., 2021) demonstrated that 3 weeks of antibiotic therapy was non-inferior to 6 weeks following surgical debridement in forefoot DFO. The 2023 IWGDF/IDSA guidelines now recommend no more than 6 weeks of antibiotic therapy for medically managed DFO, and shorter courses (as few as 2–3 weeks post-surgery) when complete bone resection has been achieved.
Oral antibiotic regimens with high bioavailability — such as fluoroquinolones, co-trimoxazole, or clindamycin — have largely replaced prolonged intravenous therapy for stable patients, improving tolerability and reducing hospital burden.
Clinical Takeaways
Diabetic foot osteomyelitis is a clinically complex condition requiring a structured, multidisciplinary approach. Early diagnosis — anchored by the probe-to-bone test, plain radiographs, and MRI when needed — remains foundational to guiding appropriate treatment. Bone biopsy provides the most reliable microbiological data and should be performed when the diagnosis is uncertain or when antibiotic therapy is the primary management strategy. Surgical intervention, when necessary, should aim for conservative resection to maximize limb function. Antibiotic treatment durations are trending shorter, especially following successful surgical debridement, reflecting a shift toward evidence-based, patient-centred care.
References
- Senneville É, Albalawi Z, van Asten SA, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-Related Foot Infections. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad527
- Ansert E, Beom J, Wukich DK, et al. Update of biomarkers to diagnose diabetic foot osteomyelitis: A meta-analysis and systematic review. Wound Repair and Regeneration. 2024. doi:10.1111/wrr.13174
- Senneville É, Joulie D, Lazaro E, et al. Percutaneous Bone Biopsy for Diabetic Foot Osteomyelitis: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases. 2020;73(7):e1539–e1547.
- Teh J, Suppiah R, Sian P, Kamath S. Magnetic Resonance Imaging of Diabetic Foot Osteomyelitis: Imaging Accuracy in Biopsy-Proven Disease. Journal of the American Podiatric Medical Association. 2020.
- Lázaro-Martínez JL, Tardáguila-García A, García-Klepzig JL. Treating Diabetic Foot Osteomyelitis: A Practical State-of-the-Art Update. Medicina. 2021;57(4):339.
- Tone A, Nguyen S, Devemy F, et al. Six-Week Versus Twelve-Week Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis. Diabetes Care. 2015;38(2):302–307.
Comments
